A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
RBD
SARS-CoV-2
antibody
macaque
neutralizing
spike
vaccine
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
pubmed:
15
1
2021
medline:
15
1
2021
entrez:
14
1
2021
Statut:
epublish
Résumé
Vaccines that generate robust and long-lived protective immunity against SARS-CoV-2 infection are urgently required. We assessed the potential of vaccine candidates based on the SARS-CoV-2 spike in cynomolgus macaques ( A robust IgG response to the spike protein was detected as early as 2 weeks after immunization with either protein and maintained for over 20 weeks. Sera from animals immunized with antigens derived from the RBD were able to prevent binding of soluble spike proteins to the ACE2 receptor, shown by These data support the utility of spike subunit-based antigens as a vaccine for use in humans.
Sections du résumé
Background
UNASSIGNED
Vaccines that generate robust and long-lived protective immunity against SARS-CoV-2 infection are urgently required.
Methods
UNASSIGNED
We assessed the potential of vaccine candidates based on the SARS-CoV-2 spike in cynomolgus macaques (
Results
UNASSIGNED
A robust IgG response to the spike protein was detected as early as 2 weeks after immunization with either protein and maintained for over 20 weeks. Sera from animals immunized with antigens derived from the RBD were able to prevent binding of soluble spike proteins to the ACE2 receptor, shown by
Conclusions
UNASSIGNED
These data support the utility of spike subunit-based antigens as a vaccine for use in humans.
Identifiants
pubmed: 33442678
doi: 10.21203/rs.3.rs-137857/v1
pmc: PMC7805460
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI078788
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI064003
Pays : United States
Déclaration de conflit d'intérêts
Competing interests. KL and is an employee and shareholder of Intuitive Biosciences. GB is an employee of Intuitive Biosciences. FS is a founder and employee of Lytic Solutions. DR is an employee of Lytic Solutions. DC and JF are current or former employees of Covance Greenfield Laboratories. KM, MB, and LM are employees of Novartis. The remaining authors declare no conflict of interests.
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Front Immunol. 2020 Aug 19;11:1880
pubmed: 32973779
Nat Struct Mol Biol. 2020 Sep;27(9):846-854
pubmed: 32661423
Biochem J. 2021 Oct 15;478(19):3671-3684
pubmed: 34558627
Pediatr Infect Dis J. 2000 Dec;19(12):1135-40
pubmed: 11144372
J Transl Med. 2020 Jun 3;18(1):222
pubmed: 32493510
J Med Virol. 2021 Apr;93(4):2115-2131
pubmed: 33091154
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
J Phys Chem B. 2020 Aug 27;124(34):7336-7347
pubmed: 32790406
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Elife. 2020 Oct 28;9:
pubmed: 33112236
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Lancet. 2004 Jun 26;363(9427):2122-7
pubmed: 15220033
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Vaccine. 2017 Aug 16;35(35 Pt B):4523-4531
pubmed: 28739115
Chem Commun (Camb). 2020 Aug 7;56(61):8683-8686
pubmed: 32613971
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
MMWR Morb Mortal Wkly Rep. 2003 Mar 14;52(10):203-4
pubmed: 12653460
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Exp Med. 2003 Mar 17;197(6):789-99
pubmed: 12642606
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Sci Transl Med. 2020 Aug 5;12(555):
pubmed: 32690628
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
Membranes (Basel). 2020 Aug 30;10(9):
pubmed: 32872641
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Front Immunol. 2020 Oct 07;11:576622
pubmed: 33117378
Vaccine. 2018 Jun 18;36(26):3809-3819
pubmed: 29778517
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Vaccine. 2020 Jul 31;38(35):5653-5658
pubmed: 32651113
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Curr Opin Biotechnol. 2011 Dec;22(6):868-76
pubmed: 21862310
Science. 2020 Nov 27;370(6520):1089-1094
pubmed: 33082295
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
J Immunol. 2006 May 15;176(10):6085-92
pubmed: 16670317
Virology. 2009 Oct 10;393(1):144-50
pubmed: 19683779
Biochem Biophys Res Commun. 2009 Jul 10;384(4):486-90
pubmed: 19422787
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
J Med Virol. 2021 Feb;93(2):892-898
pubmed: 32691875
Vaccines (Basel). 2014 Sep 02;2(3):654-85
pubmed: 26344751
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Cells. 2020 Oct 22;9(11):
pubmed: 33105869